Endurance Bio

Endurance Bio is a privately held biotechnology company based in California, USA, dedicated to developing T-168 and T-621—orally bioavailable small molecule compounds. These candidates are designed to normalize mitochondrial and lysosomal functions by activating PGC-1α and TFEB. The company is set to initiate a Phase 2 clinical trial for Parkinson’s disease, supported by the SLEIPNIR Platform*.

*The SLEIPNIR Platform is a Norway-based innovative clinical trial initiative designed to accelerate the development of Parkinson’s disease (PD) treatments. Led by the Neuro-SysMed Center at the University of Bergen and Haukeland University Hospital, the platform is funded by international charities, including Cure Parkinson’s.